Normal view MARC view ISBD view

Report from Session III of the Second International Colloquium on Cardio-oncology: Cardio-oncological management of patients. [Review]

MedStar author(s):

Citation: Seminars in Oncology. 46(6):408-413, 2019 12.PMID: 31784042Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Antineoplastic Agents/ae [Adverse Effects] | *Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects] | *Cardiovascular Diseases/et [Etiology] | *Medical Oncology | *Neoplasms/co [Complications] | Antineoplastic Agents/tu [Therapeutic Use] | Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] | Cardiotoxicity | Cardiovascular Diseases/di [Diagnosis] | Cardiovascular Diseases/pc [Prevention & Control] | Cardiovascular Diseases/th [Therapy] | Disease Management | Humans | Medical Oncology/mt [Methods] | Medical Oncology/st [Standards] | Molecular Targeted Therapy/ae [Adverse Effects] | Molecular Targeted Therapy/mt [Methods] | Neoplasms/th [Therapy]Year: 2019 Local holdings: Available online through MWHC library: 2002 - 2010, Available in print through MWHC library: 1999 - 2008ISSN:

0093-7754

Name of journal: Seminars in oncologyAbstract: Session III of the Second International Colloquium on Cardio-Oncology focused on the diagnosis, management, and prevention of cardiovascular toxicity of cancer drugs. With a large menu of biomarkers and imaging modalities available to the cardio oncologist, there continues to be no consensus regarding the best use of each modality alone and in combination and whether we can actually prevent early and late cardiotoxicity using these tests to guide a preventive strategy. It has become increasingly clear that early diagnosis and intervention leads to less late cardiotoxicity and fewer cardiac-related events. This can be accomplished by taking a thorough history and performing a goal directed physical examination coupled with use of biomarkers and imaging studies. This session attempted to provide rationale for a current and integrated approach to these issues. Copyright (c) 2019 Elsevier Inc. All rights reserved.All authors: Barac A, Cardinale DM, Khandheria BK, Lenihan D, Minotti G, Torbicki AOriginally published: Seminars in Oncology. 2019 Nov 19Fiscal year: FY2020Digital Object Identifier:

https://dx.doi.org/10.1053/j.seminoncol.2019.11.002

Date added to catalog: 2019-12-17

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	31784042	Available		31784042

Available online through MWHC library: 2002 - 2010, Available in print through MWHC library: 1999 - 2008

Session III of the Second International Colloquium on Cardio-Oncology focused on the diagnosis, management, and prevention of cardiovascular toxicity of cancer drugs. With a large menu of biomarkers and imaging modalities available to the cardio oncologist, there continues to be no consensus regarding the best use of each modality alone and in combination and whether we can actually prevent early and late cardiotoxicity using these tests to guide a preventive strategy. It has become increasingly clear that early diagnosis and intervention leads to less late cardiotoxicity and fewer cardiac-related events. This can be accomplished by taking a thorough history and performing a goal directed physical examination coupled with use of biomarkers and imaging studies. This session attempted to provide rationale for a current and integrated approach to these issues. Copyright (c) 2019 Elsevier Inc. All rights reserved.

English